COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report
Open Access
- 11 October 2021
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 196 (3) , 559-565
Abstract
Summary: Limited information is available on the impact of the COVID‐19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS‐CoV‐2‐positive patients (2·5%). Most patients (57%) were diagnosed as having SARS‐CoV‐2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty‐six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS‐CoV‐2 infection was six years (three months to 18 years). Twenty‐one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty‐three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID‐19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS‐CoV‐2 infection and an impact of the pandemic on the overall management of CML patients.Keywords
This publication has 14 references indexed in Scilit:
- Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluationJournal of Medical Virology, 2020
- Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort studyLeukemia, 2020
- Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML surveyLeukemia, 2020
- Philadelphia‐positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID‐19 pandemic: a Campus ALL studyBritish Journal of Haematology, 2020
- COVID-19 in persons with chronic myeloid leukaemiaLeukemia, 2020
- COVID-19 in persons with haematological cancersLeukemia, 2020
- Potentially highly potent drugs for 2019-nCoVbioRxiv, 2020
- Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitorsJournal of General Virology, 2018
- Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus FusionJournal of Virology, 2016
- Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemiaLeukemia, 2015